{"nctId":"NCT02397889","briefTitle":"Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD)","startDateStruct":{"date":"2015-05-18"},"conditions":["Posttraumatic Stress Disorder (PTSD)"],"count":30,"armGroups":[{"label":"Experimental ketamine group","type":"EXPERIMENTAL","interventionNames":["Drug: Ketamine"]},{"label":"Active control midazolam group","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Midazolam"]}],"interventions":[{"name":"Ketamine","otherNames":["Generic only"]},{"name":"Midazolam","otherNames":["Generic only"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men or women, 18-65 years of age;\n* Participants must have a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign a written informed consent document;\n* Participants must fulfill DSM-5 criteria for current civilian or combat-related PTSD\n* Women must be using a medically accepted reliable means of contraception (if using an oral contraceptive medication, they must also be using a barrier contraceptive) or not be of childbearing potential (i.e., surgically sterile, postmenopausal for at least one year);\n* Women of childbearing potential must have a negative pregnancy test at screening and prior to each intravenous infusion;\n* Participants must be able to identify a family member, physician, or friend (i.e. someone who knows them well) who will participate in a Treatment Contract (and e.g. contact the study physician on their behalf in case manic symptoms or suicidal thoughts develop).\n\nExclusion criteria:\n\n* Women who plan to become pregnant, are pregnant or are breast-feeding\n* Serious, unstable medical illnesses such as hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease, including gastro-esophageal reflux disease, obstructive sleep apnea, history of difficulty with airway management during previous anesthetics, ischemic heart disease and uncontrolled hypertension, and history of severe head injury;\n* Clinically significant abnormal findings of laboratory parameters, physical examination, or ECG;\n* Renal impairment, as reflected by a BUN \\>20 mg/dL, and/or creatinin clearance of \\>1.3 mg/dL;\n* Thyroid impairment, as reflected by TSH\\> 4.2 mU/L Patients with uncorrected hypothyroidism or hyperthyroidism;\n* Hormonal treatment (e.g., estrogen) started in the 3 months prior to the first infusion day;\n* Use of evidence-based individual psychotherapy (such as prolonged exposure) during the study;\n* History of autism, mental retardation, pervasive developmental disorders, or Tourette's syndrome; History of one or more seizures without a clear and resolved etiology;\n* History of (hypo)mania;\n* Past or current presence of psychotic symptoms, or diagnosis of a lifetime psychotic disorder including schizophrenia or schizoaffective disorder;\n* Drug or alcohol abuse or dependence within the preceding 3 months\n* Previous recreational use of ketamine or PCP;\n* Current diagnosis of bulimia nervosa or anorexia nervosa;\n* Diagnosis of schizotypal or antisocial personality disorder\n* Patients judged clinically to be at serious and imminent suicidal or homicidal risk.\n* A blood pressure of one reading over 160/90 or two separate readings over 140/90 at screen or baseline visits\n* Patients who report current treatment with a benzodiazepine, an opioid medication, or a mood stabilizer (such as valproic acid or lithium) within 2 weeks prior to randomization","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)","description":"full range score from 0-80, with higher scores indicating greater PTSD symptoms","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.5","spread":"14.4"},{"groupId":"OG001","value":"33.2","spread":"11.8"}]}]}]},{"type":"SECONDARY","title":"The Impact of Event Scale - Revised (IES-R)","description":"full range score from 0-88, with higher scores indicating greater PTSD symptoms","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":"15.2"},{"groupId":"OG001","value":"24.8","spread":"13.1"}]}]}]},{"type":"SECONDARY","title":"Montgomery Asberg Depression Rating Scale (MADRS)","description":"full range score from 0-60, with higher scores indicating greater depressive symptoms","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.5","spread":"9.6"},{"groupId":"OG001","value":"17.1","spread":"9.4"}]}]}]},{"type":"SECONDARY","title":"Montgomery Asberg Depression Rating Scale (MADRS)","description":"full range score from 0-60, with higher scores indicating greater depressive symptoms","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","spread":"12.1"},{"groupId":"OG001","value":"21.9","spread":"8.5"}]}]}]},{"type":"SECONDARY","title":"Quick Inventory of Depression Symptomatology - Self-Report (QIDS-SR)","description":"full range score from 0-27, with higher scores indicating greater depressive symptoms","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","spread":"7.1"},{"groupId":"OG001","value":"6.7","spread":"5.4"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Patient-Rated Inventory of Side Effects (PRISE)","description":"All side effects listed in Adverse Event section.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":["Other","Fatigue","Nausea/Vomiting","Headache","Blurred vision"]}}}